Septic Shock, Severe Sepsis
Conditions
Keywords
Emergency Department, Hemodynamic Optimization, Esophageal Doppler monitoring, Early Goal-Directed Therapy
Brief summary
Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality. However, this approach requires invasive hemodynamic monitoring, thus limiting its widespread application in the emergency department setting. A minimally invasive protocol utilizing esophageal Doppler monitoring (EDM) may be of benefit and practical if it is shown to result in similar outcome as EGDT.
Interventions
6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult patients \>= 18 years old * Source of infection * Two or more of systemic inflammatory response syndrome criteria * Systolic blood pressure \< 90 mmHg after a fluid bolus OR lactate \>= 4 mmol/L * A central line has been placed for CVP/ScvO2 monitoring
Exclusion criteria
* Pregnancy * Acute stroke * Acute cardiogenic pulmonary edema * Status asthmaticus * Unstable cardiac dysrhythmia * Active hemorrhage * Acute seizure * Drug overdose * Trauma * Requiring immediate surgery * Do-not-resuscitate status
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | hospital | In-hospital mortality |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MiCHO A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
Esophageal Doppler monitoring - CardioQ, Deltex Inc: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM | 2 |
| EGDT A 6-hour resuscitation protocol utilizing CVP/ScvO2
Central line with CVP and continuous ScvO2 monitoring: 6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring | 3 |
| Total | 5 |
Baseline characteristics
| Characteristic | MiCHO | EGDT | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 0 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 3 Participants | 3 Participants |
| Age, Continuous | 81.5 years STANDARD_DEVIATION 10.5 | 60.7 years STANDARD_DEVIATION 1.2 | 69.0 years STANDARD_DEVIATION 6.1 |
| Region of Enrollment United States | 2 participants | 3 participants | 5 participants |
| SBP < 90 or Lactate >= 4 mmol/L | 2 participants | 3 participants | 5 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 2 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 2 | 0 / 3 |
| serious Total, serious adverse events | 0 / 2 | 0 / 3 |
Outcome results
Mortality
In-hospital mortality
Time frame: hospital
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MiCHO | Mortality | 0 participants |
| EGDT | Mortality | 0 participants |